Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 218

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia

Open access
Yin, Wu, Carballo-Jane, Ester, McLaren, David G., Mendoza, Vivienne H., Gagen, Karen, Geoghagen, Neil S., McNamara, Lesley Ann, Gorski, Judith N., Eiermann, George J., Petrov, Aleksandr, Wolff, Michael, Tong, Xinchun, Wilsie, Larissa C., Akiyama, Taro E., Chen, Jing, Thankappan, Anil, Xue, Jiyan, Ping, Xiaoli, Andrews, Genevieve, Wickham, L. Alexandra, Gai, Cesaire L., Trinh, Tu, Kulick, Alison A., Donnelly, Marcie J., Voronin, Gregory O., Rosa, Ray, Cumiskey, Anne-Marie, Bekkari, Kavitha, Mitnaul, Lyndon J., Puig, Oscar, Chen, Fabian, Raubertas, Richard, Wong, Peggy H., Hansen, Barbara C., Koblan, Ken S., Roddy, Thomas P., Hubbard, Brian K, Strack, Alison M.·2012·Journal of Lipid Research

Abstract

In an attempt to understand the applicability of various animal models to dyslipidemia in humans and to identify improved preclinical models for target discovery and validation for dyslipidemia, we measured comprehensive plasma lipid profiles in 24 models. These included five mouse strains, six other nonprimate species, and four nonhuman primate (NHP) species, and both healthy animals and animals with metabolic disorders. Dyslipidemic humans were assessed by the same measures. Plasma lipoprotein profiles, eight major plasma lipid fractions, and FA compositions within these lipid fractions were compared both qualitatively and quantitatively across the species. Given the importance of statins in decreasing plasma low-density lipoprotein cholesterol for treatment of dyslipidemia in humans, the responses of these measures to simvastatin treatment were also assessed for each species and compared with dyslipidemic humans. NHPs, followed by dog, were the models that demonstrated closest overall match to dyslipidemic humans. For the subset of the dyslipidemic population with high plasma triglyceride levels, the data also pointed to hamster and db/db mouse as representative models for practical use in target validation. Most traditional models, including rabbit, Zucker diabetic fatty rat, and the majority of mouse models, did not demonstrate overall similarity to dyslipidemic humans in this study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1194/jlr.m019927

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 54

  1. Yusuf, 2001, Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization, Circulation., 104, 2746, 10.1161/hc4601.099487 · DOI · Paper page
  2. Paramsothy, 2006, Management of dyslipidaemias, Heart., 92, 1529, 10.1136/hrt.2005.071712 · DOI
  3. Sharma, 2009, Systemic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia, Ann. Intern. Med., 151, 622, 10.7326/0003-4819-151-9-200911030-00144 · DOI · Paper page
  4. Cannon, 2008, Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes, Am. Heart J., 156, 826, 10.1016/j.ahj.2008.07.023 · DOI · Paper page
  5. Alagona, 2009, Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy, Am. J. Manag. Care., 15, S65
  6. Russell, 2006, Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis, Cardiovasc. Pathol., 15, 318, 10.1016/j.carpath.2006.09.001 · DOI · Paper page
  7. Tsutsumi, 2001, The relationship between plasma high density lipoprotein cholesterol levels and cholesteryl ester transfer protein activity in six species of healthy experimental animals, Biol. Pharm. Bull., 24, 579, 10.1248/bpb.24.579 · DOI
  8. Ishibashi, 1993, Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery, J. Clin. Invest., 92, 883, 10.1172/JCI116663 · DOI · Paper page
  9. Harada, 2006, Regulation of hepatic cholesterol metabolism in CETP/LDLr mice by cholesterol feeding and by drugs (cholestyramine and lovastatin) that lower plasma cholesterol, Clin. Exp. Pharmacol. Physiol., 33, 1209, 10.1111/j.1440-1681.2006.04512.x · doi:10.1111/j.1440-1681.2006.04512.x
  10. Van Eck, 2007, Important role for bone marrow-derived cholesteryl ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice, Circ. Res., 100, 678, 10.1161/01.RES.0000260202.79927.4f · DOI
  11. Kolodgie, 1996, Hypercholesterolemia in the rabbit induced by feeding graded amounts of low-level cholesterol. Methodological considerations regarding individual variability in response to dietary cholesterol and development of lesion type, Arterioscler. Thromb. Vasc. Biol., 16, 1454, 10.1161/01.ATV.16.12.1454 · DOI
  12. 2001, Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III), J. Am. Med. Assoc., 285, 2486, 10.1001/jama.285.19.2486 · DOI · Paper page
  13. Kontush, 2010, Lipidomics as a tool for the study of lipoprotein metabolism, Curr. Atheroscler. Rep., 12, 194, 10.1007/s11883-010-0100-0 · DOI
  14. Ekroos, 2010, Lipidomics: a tool for studies of atherosclerosis, Curr. Atheroscler. Rep., 12, 273, 10.1007/s11883-010-0110-y · DOI
  15. Chen, 2011, The effects of simvastatin treatment on plasma lipid-related biomarkers in men with dyslipidaemia, Biomarkers., 16, 321, 10.3109/1354750X.2011.561367 · DOI
  16. Bajpai, 2010, Should we measure C-reactive protein on earth or just on JUPITER?, Clin. Cardiol., 33, 190, 10.1002/clc.20681 · DOI
  17. 28., Genest, J., C-reactive protein: risk factor, biomarker and/or therapeutic target? Can. J. Cardiol. 26 (Suppl A): 41–44. · DOI
  18. Claus, 1976, Radioimmunoassay of human C-reactive protein and levels in normal sera, J. Lab. Clin. Med., 87, 120
  19. Tomassini, 2009, Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia, Diabetes Obes. Metab., 11, 855, 10.1111/j.1463-1326.2009.01061.x · DOI
  20. Cross, 2004, Saliva sampling to assess cortisol levels in unrestrained common marmosets and the effect of behavioral stress, Am. J. Primatol., 62, 107, 10.1002/ajp.20005 · DOI
  21. Harchaoui, 2009, Triglycerides and cardiovascular risk, Curr. Cardiol. Rev., 5, 216, 10.2174/157340309788970315 · DOI
  22. Grove, 1991, Comparative specificity of plasma lecithin:cholesterol acyltransferase from ten animal species, Lipids., 26, 416, 10.1007/BF02536066 · DOI
  23. Rousset, 2009, Lecithin:cholesterol acyltransferase–from biochemistry to role in cardiovascular disease, Curr. Opin. Endocrinol. Diabetes Obes., 16, 163, 10.1097/MED.0b013e328329233b · DOI · Paper page
  24. Chang, 2001, Roles of acyl-coenzyme A:cholesterol acyltransferase-1 and -2, Curr. Opin. Lipidol., 12, 289, 10.1097/00041433-200106000-00008 · DOI · Paper page
  25. Lee, 2004, Plasma cholesteryl esters provided by lecithin:cholesterol acyltransferase and acyl-coenzyme a:cholesterol acyltransferase 2 have opposite atherosclerotic potential, Circ. Res., 95, 998, 10.1161/01.RES.0000147558.15554.67 · DOI · Paper page
  26. Cho, 1998, A peptide from hog plasma that inhibits human cholesteryl ester transfer protein, Biochim. Biophys. Acta., 1391, 133, 10.1016/S0005-2760(97)00197-5 · DOI
  27. Guyard-Dangremont, 1998, Phospholipid and cholesteryl ester transfer activities in plasma from 14 vertebrate species. Relation to atherogenesis susceptibility, Comp. Biochem. Physiol. B Biochem. Mol. Biol., 120, 517, 10.1016/S0305-0491(98)10038-X · DOI
  28. Oliveira, 1996, J. Biol. Chem., 271, 31831, 10.1074/jbc.271.50.31831 · DOI
  29. Jiang, 1992, Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences, J. Clin. Invest., 90, 1290, 10.1172/JCI115993 · DOI · Paper page
  30. Quinet, 1990, Atherogenic diet increases cholesteryl ester transfer protein messenger RNA levels in rabbit liver, J. Clin. Invest., 85, 357, 10.1172/JCI114446 · DOI
  31. Gal, 1990, Atherosclerotic Yucatan microswine: an animal model with high-grade, fibrocalcific, nonfatty lesions suitable for testing catheter-based interventions, Am. Heart J., 119, 291, 10.1016/S0002-8703(05)80019-5 · doi:10.1016/s0002-8703(05)80019-5
  32. Dixon, 2002, Increased atherosclerosis in diabetic dyslipidemic swine: protection by atorvastatin involves decreased VLDL triglycerides but minimal effects on the lipoprotein profile, J. Lipid Res., 43, 1618, 10.1194/jlr.M200134-JLR200 · DOI
  33. Berkhout, 1997, SR-12813 lowers plasma cholesterol in beagle dogs by decreasing cholesterol biosynthesis, Atherosclerosis., 133, 203, 10.1016/S0021-9150(97)00131-7 · DOI
  34. Hough, 1975, Cholesterol kinetic analysis in normal and cholesterol-fed rabbits; effects of saturated versus polyunsaturated fat and of cholestyramine, J. Nutr., 105, 649, 10.1093/jn/105.6.649 · doi:10.1093/jn/105.6.649
  35. Clay, 1989, The rabbit as an animal model of hepatic lipase deficiency, Biochim. Biophys. Acta., 1002, 173, 10.1016/0005-2760(89)90284-1 · DOI
  36. Chang, 1993, Hepatic lipase function and the accumulation of beta-very-low-density lipoproteins in the plasma of cholesterol-fed rabbits, Biochem. J., 293, 745, 10.1042/bj2930745 · DOI
  37. Uelmen, 1995, Tissue-specific expression and cholesterol regulation of acylcoenzyme A:cholesterol acyltransferase (ACAT) in mice. Molecular cloning of mouse ACAT cDNA, chromosomal localization, and regulation of ACAT in vivo and in vitro, J. Biol. Chem., 270, 26192, 10.1074/jbc.270.44.26192 · DOI
  38. Downs, 1993, Plasma lipoprotein lipids in five different breeds of dogs, Res. Vet. Sci., 54, 63, 10.1016/0034-5288(93)90012-5 · DOI
  39. Tardif, 2009, Characterization of obese phenotypes in a small nonhuman primate, the common marmoset (Callithrix jacchus), Obesity (Silver Spring)., 17, 1499, 10.1038/oby.2009.77 · DOI
  40. Yang, 2009, Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia, Am. J. Cardiovasc. Drugs., 9, 401, 10.2165/11203920-000000000-00000 · DOI
  41. Serisier, 2006, Fenofibrate lowers lipid parameters in obese dogs, J. Nutr., 136, 2037, 10.1093/jn/136.7.2037S · DOI
  42. Srivastava, 2010, Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster, Mol. Cell. Biochem., 345, 197, 10.1007/s11010-010-0573-8 · DOI
  43. Krause, 1998, Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice?, Atherosclerosis., 140, 15, 10.1016/S0021-9150(98)00141-5 · DOI
  44. Harris, 1996, n-3 fatty acids and lipoproteins: comparison of results from human and animal studies, Lipids., 31, 243, 10.1007/BF02529870 · DOI · Paper page
  45. Patel, 2009, Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy, Vasc. Health Risk Manag., 5, 801, 10.2147/VHRM.S4307 · DOI
  46. Lusis, 2000, Atherosclerosis, Nature., 407, 233, 10.1038/35025203 · DOI · Paper page
  47. Shi, 2009, Vulnerable plaque in a Swine model of carotid atherosclerosis, AJNR Am. J. Neuroradiol., 30, 469, 10.3174/ajnr.A1410 · doi:10.3174/ajnr.a1410
  48. Kagawa, 1998, Systemic atherosclerosis in dogs: histopathological and immunohistochemical studies of atherosclerotic lesions, J. Comp. Pathol., 118, 195, 10.1016/S0021-9975(05)80126-4 · doi:10.1016/s0021-9975(05)80126-4
  49. Dillard, 2010, Use of hamster as a model to study diet-induced atherosclerosis, Nutr. Metab. (Lond)., 7, 89, 10.1186/1743-7075-7-89 · DOI
  50. Lands, 1960, Metabolism of glycerolipids. II. The enzymatic acylation of lysolecithin, J. Biol. Chem., 235, 2233, 10.1016/S0021-9258(18)64604-6 · DOI · Paper page
  51. Lands, 1963, Metabolism of glycerolipids. III. Reactivity of various acyl esters of coenzyme A with alpha’-acylglycerophosphorylcholine, and positional specificities in lecithin synthesis, J. Biol. Chem., 238, 898, 10.1016/S0021-9258(18)81234-0 · DOI · Paper page
  52. Jezyk, 1968, Specificity of acyl-CoA: phospholipid acyltransferases: solvent and temperature effects, J. Lipid Res., 9, 525, 10.1016/S0022-2275(20)42733-6 · doi:10.1016/s0022-2275(20)42733-6
  53. Abd, 2011, The role of C-reactive protein as a risk predictor of coronary atherosclerosis: implications from the JUPITER trial, Curr. Atheroscler. Rep., 13, 154, 10.1007/s11883-011-0164-5 · DOI
  54. Jinbo, 1998, Development of monkey C-reactive protein (CRP) assay methods, Vet. Immunol. Immunopathol., 61, 195, 10.1016/S0165-2427(97)00148-7 · doi:10.1016/s0165-2427(97)00148-7

Cited by

See all 218

Metadata

Authors
Yin, W., Carballo-Jane, E., McLaren, D. G., Mendoza, V. H., Gagen, K., Geoghagen, N. S., McNamara, L. A., Gorski, J. N., Eiermann, G. J., Petrov, A., Wolff, M., Tong, X., Wilsie, L. C., Akiyama, T. E., Chen, J., Thankappan, A., Xue, J., Ping, X., Andrews, G., Wickham, L. A., Gai, C. L., Trinh, T., Kulick, A. A., Donnelly, M. J., Voronin, G. O., Rosa, R., Cumiskey, A.-M., Bekkari, K., Mitnaul, L. J., Puig, O., Chen, F., Raubertas, R., Wong, P. H., Hansen, B. C., Koblan, K. S., Roddy, T. P., Hubbard, B. K., & Strack, A. M.
Venue
Journal of Lipid Research
Publisher
Elsevier BV
Published
2012-01
Volume
53
Issue
1
Pages
51-65
ISSN
0022-2275 (ISSN-L)
OpenAlex
W2111563461
Cited by
218
References
14
FWCI
7.53
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. https://app.cochat.ai/papers/10.1194/jlr.m019927
The paper
Yin, W., Carballo-Jane, E., McLaren, D. G., Mendoza, V. H., Gagen, K., Geoghagen, N. S., McNamara, L. A., Gorski, J. N., Eiermann, G. J., Petrov, A., Wolff, M., Tong, X., Wilsie, L. C., Akiyama, T. E., Chen, J., Thankappan, A., Xue, J., Ping, X., Andrews, G., . . . Strack, A. M. (2012). Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. Journal of Lipid Research. https://doi.org/10.1194/jlr.m019927

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.